Home LiteratureArticle Details
PMID: 18221429 Published · ppublish English Journal Article Review

Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data.

Pediatric diabetes ·Vol. 9 ·No. 3 Pt 2 ·2008-06-00 ·Pages 14-22

Brown RJ, Rother KI

Abstract

暂无摘要

MeSH Terms
Adult C-Peptide/metabolism Child Clinical Trials as Topic Dendritic Cells/immunology,transplantation Diabetes Mellitus, Type 1/drug therapy,immunology Glucose/physiology Humans Hypoglycemic Agents/therapeutic use Insulin/metabolism,therapeutic use Insulin Secretion Insulin-Secreting Cells/immunology,metabolism Models, Biological Oxidative Stress/drug effects,immunology,physiology
Chemicals
C-Peptide Hypoglycemic Agents Insulin Glucose
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Brown Rebecca J
Clinical Endocrinology Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Rother Kristina I
References (63)
63 references, click to expand
  1. Improvement in insulin secretion in diabetes after diazoxide.
    Lancet. 1976 Feb 28;1(7957):444-7 PMID: 55717
  2. Diazoxide and the treatment of hypoglycemia: an historical review.
    Ann N Y Acad Sci. 1968 Apr 11;150(2):194-203 PMID: 4875708
  3. Hyperglycemia and hyperinsulinemia have additive effects on activation and proliferation of pancreatic stellate cells: possible explanation of islet-specific fibrosis in type 2 diabetes mellitus.
    J Cell Biochem. 2007 Jun 1;101(3):665-75 PMID: 17212361
  4. Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes.
    Diabetes Metab. 2002 Dec;28(6 Pt 1):448-56 PMID: 12522324
  5. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.
    Diabetes Care. 1997 Sep;20(9):1353-6 PMID: 9283777
  6. Diabetes prevention in BB rats by inhibition of endogenous insulin secretion.
    Metabolism. 1991 Aug;40(8):825-9 PMID: 1907346
  7. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes.
    Acta Endocrinol (Copenh). 1988 Jul;118(3):365-73 PMID: 3293339
  8. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders.
    Curr Med Chem. 2004 Jun;11(12):1595-615 PMID: 15180566
  9. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial.
    J Clin Endocrinol Metab. 2003 Jun;88(6):2586-92 PMID: 12788859
  10. Insulin treatment improves glucose-induced insulin release in rats with NIDDM induced by streptozocin.
    Diabetes. 1987 Aug;36(8):971-7 PMID: 3297892
  11. Beta-cell rest: a strategy for the prevention of autoimmune diabetes.
    Autoimmunity. 1997;26(2):117-22 PMID: 9546813
  12. Subtotal pancreatectomy for hypoglycemia due to congenital hyperinsulinism: long-term follow-up of neurodevelopmental and pancreatic function.
    Pediatr Diabetes. 2001 Sep;2(3):115-22 PMID: 15016194
  13. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
    Diabetes Care. 2005 May;28(5):1068-76 PMID: 15855569
  14. Effects of timely insulin treatment on protection of beta cells in a rat model of type 2 diabetes mellitus.
    Chin Med J (Engl). 2004 Oct;117(10):1523-9 PMID: 15498377
  15. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes.
    Am J Physiol Endocrinol Metab. 2000 Sep;279(3):E520-8 PMID: 10950818
  16. Intensive insulin therapy protects the endothelium of critically ill patients.
    J Clin Invest. 2005 Aug;115(8):2277-86 PMID: 16075063
  17. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    JAMA. 1999 Jun 2;281(21):2005-12 PMID: 10359389
  18. Peptide-binding G protein-coupled receptors: new opportunities for drug design.
    Curr Med Chem. 2001 Nov;8(13):1605-48 PMID: 11562281
  19. Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus.
    Metabolism. 2006 May;55(5):691-5 PMID: 16631447
  20. The biology of incretin hormones.
    Cell Metab. 2006 Mar;3(3):153-65 PMID: 16517403
  21. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets.
    Diabetes. 2004 Jul;53(7):1706-13 PMID: 15220194
  22. TLR4 links innate immunity and fatty acid-induced insulin resistance.
    J Clin Invest. 2006 Nov;116(11):3015-25 PMID: 17053832
  23. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes.
    Endocr Rev. 2002 Oct;23(5):599-622 PMID: 12372842
  24. Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide.
    Diabetes Care. 1998 Mar;21(3):427-30 PMID: 9540027
  25. Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells.
    Diabetes. 2005 Sep;54(9):2602-11 PMID: 16123348
  26. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes.
    Diabetes. 1996 Oct;45(10):1427-30 PMID: 8826981
  27. Long-term prophylactic insulin treatment can prevent spontaneous diabetes and thyroiditis development in the diabetes-prone bio-breeding rat, while short-term treatment is ineffective.
    Eur J Endocrinol. 2003 Sep;149(3):223-9 PMID: 12943525
  28. K(ATP) channel openers protect rat islets against the toxic effect of streptozotocin.
    Diabetes. 2000 Jul;49(7):1131-6 PMID: 10909969
  29. Metabolic diapause in pancreatic beta-cells expressing a gain-of-function mutant of the forkhead protein Foxo1.
    J Biol Chem. 2007 Jan 5;282(1):287-93 PMID: 17107961
  30. A randomized trial of a somatostatin analog for preserving beta cell function in children with insulin dependent diabetes mellitus.
    J Pediatr Endocrinol. 1994 Oct-Dec;7(4):331-4 PMID: 7735371
  31. A comprehensive review of interventions in the NOD mouse and implications for translation.
    Immunity. 2005 Aug;23(2):115-26 PMID: 16111631
  32. Insulin granule dynamics in pancreatic beta cells.
    Diabetologia. 2003 Aug;46(8):1029-45 PMID: 12879249
  33. Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients.
    J Endocrinol Invest. 1988 Jul-Aug;11(7):501-7 PMID: 3049768
  34. Beta cell rest and recovery--does it bring patients with latent autoimmune diabetes in adults to euglycemia?
    Ann N Y Acad Sci. 2002 Apr;958:89-98 PMID: 12021087
  35. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
    Diabetes Care. 2003 Mar;26(3):832-6 PMID: 12610045
  36. Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener.
    Diabetes. 2004 Apr;53(4):1089-95 PMID: 15047626
  37. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes.
    Diabetes Care. 2004 May;27(5):1028-32 PMID: 15111515
  38. Effects of insulin in relatives of patients with type 1 diabetes mellitus.
    N Engl J Med. 2002 May 30;346(22):1685-91 PMID: 12037147
  39. Diabetes treatment--bridging the divide.
    N Engl J Med. 2007 Apr 12;356(15):1499-501 PMID: 17429082
  40. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats.
    Diabetes. 1994 Feb;43(2):173-9 PMID: 8288040
  41. Glucose regulation of the autoantigen GAD65 in human pancreatic islets.
    J Clin Endocrinol Metab. 1992 Dec;75(6):1574-6 PMID: 1464667
  42. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5.
    Biochem Pharmacol. 1999 May 15;57(10):1159-64 PMID: 11230804
  43. Sustained insulin-induced remissions of juvenile diabetes by means of an external artificial pancreas.
    Diabetologia. 1978 Apr;14(4):223-7 PMID: 640299
  44. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose.
    J Clin Endocrinol Metab. 2004 Feb;89(2):795-805 PMID: 14764798
  45. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.
    Diabetes Care. 2004 Nov;27(11):2597-602 PMID: 15504992
  46. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
    Ann Intern Med. 1998 Apr 1;128(7):517-23 PMID: 9518395
  47. A functional link between glucokinase binding to insulin granules and conformational alterations in response to glucose and insulin.
    J Biol Chem. 2002 Sep 13;277(37):34168-75 PMID: 12101177
  48. Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina.
    Endocrinology. 1993 Jun;132(6):2674-81 PMID: 8504767
  49. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals.
    Diabetologia. 1985 Dec;28(12):933-5 PMID: 4092862
  50. Short-term intermittent exposure to diazoxide improves functional performance of beta-cells in a high-glucose environment.
    Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1202-8 PMID: 15292032
  51. Chronic suppression of insulin by diazoxide alters the activities of key enzymes regulating hepatic gluconeogenesis in Zucker rats.
    Eur J Endocrinol. 2002 Jun;146(6):871-9 PMID: 12039709
  52. Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB rat monoclonal autoantibody IC2.
    APMIS. 1988 Apr;96(4):342-6 PMID: 3285866
  53. Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs.
    Biochem Biophys Res Commun. 1994 Nov 30;205(1):341-6 PMID: 7999046
  54. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration.
    J Biol Chem. 1998 Dec 11;273(50):33501-7 PMID: 9837930
  55. Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes.
    ILAR J. 2006;47(3):225-33 PMID: 16804197
  56. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice.
    Endocrinology. 2000 Jan;141(1):111-7 PMID: 10614629
  57. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats.
    Horm Metab Res. 2000 Jul;32(7):294-300 PMID: 10965937
  58. Sulfonylurea induced beta-cell apoptosis in cultured human islets.
    J Clin Endocrinol Metab. 2005 Jan;90(1):501-6 PMID: 15483097
  59. K(ATP) channels and pancreatic islet blood flow in anesthetized rats: increased blood flow induced by potassium channel openers.
    Diabetes. 2003 Aug;52(8):2043-8 PMID: 12882921
  60. Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity.
    Endocrinology. 2002 Feb;143(2):339-42 PMID: 11796484
  61. Stimulus/secretion coupling factors in glucose-stimulated insulin secretion: insights gained from a multidisciplinary approach.
    Diabetes. 2002 Dec;51 Suppl 3:S389-93 PMID: 12475781
  62. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells?
    Diabetes. 2004 Aug;53(8):1942-8 PMID: 15277370
  63. Short-term insulin therapy in adolescents with type 2 diabetes mellitus.
    J Pediatr Endocrinol Metab. 2004 Nov;17(11):1561-4 PMID: 15570994
Article Info
Journal
Pediatric diabetes
Abbr.
Pediatr Diabetes
ISSN
1399-5448
DOI
10.1111/j.1399-5448.2007.00272.x
Published
2008-06-00
Epub
2008-00-24
Pages
14-22
Language
English
Region
Denmark
NLM ID
100939345
PMCID
PMC3417290
Subset
IM
Grants
Intramural NIH HHS · ZIA DK047049-04 · United States
Intramural NIH HHS · Z01 DK047049-01 · United States
Intramural NIH HHS · ZIA DK047049-03 · United States
Intramural NIH HHS · Z01 DK047049-02 · United States
Intramural NIH HHS · Z99 DK999999 · United States
External Links
PubMed source DOI: 10.1111/j.1399-5448.2007.00272.x PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2